Načítá se...
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especi...
Uloženo v:
| Vydáno v: | Breast Care (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger GmbH
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5290437/ https://ncbi.nlm.nih.gov/pubmed/28228704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000453569 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|